Trial Profile
A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bempedoic acid/ezetimibe (Primary) ; Bempedoic acid; Ezetimibe
- Indications Cardiovascular disorders; Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Esperion Therapeutics
- 01 May 2020 Results (N= 3369), meta-analysis of data pooled from 4 clinical trials assessing the effect of Bempedoic acid on serum uric acid, published in the Drug Safety
- 06 Apr 2020 According to an Esperion Therapeutics media release,European Commission approved the NUSTENDI™ (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine for hypercholesterolemia and dyslipidemia in Europe. NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
- 26 Feb 2020 According to an Esperion Therapeutics meida release, U.S. Food and Drug Administration (FDA) approved NEXLIZET™ (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C), lowering medicine based on this trial.